Obesity

The top Managed Care Cast episodes explored wellness visits, weight loss drug access, neurospine care, public health policy, and ketamine-assisted therapy.

Glucagon-like peptide 1 (GLP-1) receptor agonists offer promise in weight and cardiovascular risk reduction, but their use must complement—not replace—lifestyle interventions within a holistic, patient-centered care model.

A phase 2 trial demonstrated substantial weight loss with the long-acting peptide–antibody conjugate, as well as other cardiometabolic improvements.

Explore the evolving landscape of biologics in metabolic syndrome treatment, highlighting GLP-1 analogs and PCSK9 inhibitors for improved patient outcomes.

The guidelines highlight the need for lifelong obesity management, early diagnosis, comorbidity prevention, and patient-centered care.

Discontinuing GLP-1 use before or early in pregnancy raises gestational weight gain, birth weight percentile, and the risk of pregnancy complications.

Research shows a sharp rise in bisphenol-attributable metabolic disease since 2000, with annual costs exceeding $250 billion in North America.

Semaglutide and tirzepatide led to the most weight loss across 22 trials, while liraglutide remains a cost-effective alternative as its patent expires.

Consistent across age, sex, and race, BMI closely mirrored body fat–based obesity in nearly all US youth with BMI-defined obesity (BDO).

Research highlights disparities in anti-obesity medication use and metabolic and bariatric surgery.

The European Association for the Study of Obesity now recommends the 2 treatments for obesity and most associated complications.

Here are 5 reasons why bariatric surgery may be better for weight loss than GLP-1 receptor agonists

Bariatric surgery is more efficient at increasing weight loss and more cost-effective than GLP-1 RAs.

Researchers in Denmark observed a significant drop-off in anti-obesity drug usage after 1 year in first-time users.

This commentary calls for health care systems to deliver equitable care for people living with obesity by addressing weight bias and updating standards in obesity care.

Bariatric surgery reduces the likelihood of obesity-related comorbidities compared with nonsurgical weight loss interventions.

This article reviews the safety, efficacy, and regulatory concerns related to compounded semaglutide, with a focus on how health care providers can offer guidance and education to patients.

While body mass index (BMI) accurately identified excess adiposity in nearly all children and adolescents with obesity, it failed to detect many of those without obesity who still had excess body fat.

Researchers call for further studies on GLP-1 initiation after bariatric surgery to better understand its real-world impact.

Male and female fat deposit distribution was associated with an increased cardiovascular age-delta; however, some adiposity phenotypes seen as beneficial in one sex were a risk in the other.

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing cancer risk among patients with obesity, particularly for endometrial, ovarian, and meningioma cancers.

Rising prescription drug costs challenge US health care, prompting calls for reform and innovative solutions to enhance affordability and access for patients.

Employers explore glucagon-like peptide-1 (GLP-1) therapies' impact on health benefits, showcasing accountability and data-driven strategies in Philadelphia, Pennsylvania, and Wilmington, Delaware, for sustainable health programs.

A recent study aimed to assess evidence on the safety and complications of preoperative glucagon-like peptide-1 (GLP-1) receptor agonist use.

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.